Genzyme CorporateResearchSearchGenzyme Websites
Patients and FamiliesHeath Care Professionals

Renagel® (sevelamer hydrochloride)

Renagel controls serum phosphorus levels without the concern of calcium or metal accumulation.

New KDOQI guidelines recommend Sevelamer as a first-line option for the reduction of phosphorus in Chronic Kidney Disease (CKD) patients on hemodialysis.1

Patients & Families Health Care Professionals



Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. Please see accompanying full Prescribing Information.

Search

Learn about Renassist, Genzyme’s reimbursement support team.
Go to the Renassist Website >

Global Availability
This website is intended for use in the United States. Renagel is also available in these countries:
Contact Information
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email
Terms and Conditions of Use | Privacy Policy |  This site is intended for United States residents only.
© 2009 Genzyme Corporation. All rights reserved. Renagel and Genzyme are registered trademarks of Genzyme Corporation